JP2013173775A5 - - Google Patents

Download PDF

Info

Publication number
JP2013173775A5
JP2013173775A5 JP2013094727A JP2013094727A JP2013173775A5 JP 2013173775 A5 JP2013173775 A5 JP 2013173775A5 JP 2013094727 A JP2013094727 A JP 2013094727A JP 2013094727 A JP2013094727 A JP 2013094727A JP 2013173775 A5 JP2013173775 A5 JP 2013173775A5
Authority
JP
Japan
Prior art keywords
vegf antibody
medicament
administered
gemcitabine
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013094727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013173775A (ja
JP6184733B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013173775A publication Critical patent/JP2013173775A/ja
Publication of JP2013173775A5 publication Critical patent/JP2013173775A5/ja
Application granted granted Critical
Publication of JP6184733B2 publication Critical patent/JP6184733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013094727A 2010-02-23 2013-04-26 卵巣癌の治療のための抗血管新生治療 Active JP6184733B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US30709510P 2010-02-23 2010-02-23
US61/307,095 2010-02-23
US35123110P 2010-06-03 2010-06-03
US61/351,231 2010-06-03
US36005910P 2010-06-30 2010-06-30
US61/360,059 2010-06-30
US201161439819P 2011-02-04 2011-02-04
US61/439,819 2011-02-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012554084A Division JP2013520442A (ja) 2010-02-23 2011-02-22 卵巣癌の治療のための抗血管新生治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015153726A Division JP2016020354A (ja) 2010-02-23 2015-08-03 卵巣癌の治療のための抗血管新生治療

Publications (3)

Publication Number Publication Date
JP2013173775A JP2013173775A (ja) 2013-09-05
JP2013173775A5 true JP2013173775A5 (enExample) 2014-04-10
JP6184733B2 JP6184733B2 (ja) 2017-08-23

Family

ID=44476669

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012554084A Withdrawn JP2013520442A (ja) 2010-02-23 2011-02-22 卵巣癌の治療のための抗血管新生治療
JP2013094727A Active JP6184733B2 (ja) 2010-02-23 2013-04-26 卵巣癌の治療のための抗血管新生治療
JP2015153726A Withdrawn JP2016020354A (ja) 2010-02-23 2015-08-03 卵巣癌の治療のための抗血管新生治療
JP2017094206A Pending JP2017193551A (ja) 2010-02-23 2017-05-10 卵巣癌の治療のための抗血管新生治療
JP2018142978A Withdrawn JP2018199683A (ja) 2010-02-23 2018-07-30 卵巣癌の治療のための抗血管新生治療
JP2020126490A Pending JP2020196719A (ja) 2010-02-23 2020-07-27 卵巣癌の治療のための抗血管新生治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012554084A Withdrawn JP2013520442A (ja) 2010-02-23 2011-02-22 卵巣癌の治療のための抗血管新生治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015153726A Withdrawn JP2016020354A (ja) 2010-02-23 2015-08-03 卵巣癌の治療のための抗血管新生治療
JP2017094206A Pending JP2017193551A (ja) 2010-02-23 2017-05-10 卵巣癌の治療のための抗血管新生治療
JP2018142978A Withdrawn JP2018199683A (ja) 2010-02-23 2018-07-30 卵巣癌の治療のための抗血管新生治療
JP2020126490A Pending JP2020196719A (ja) 2010-02-23 2020-07-27 卵巣癌の治療のための抗血管新生治療

Country Status (20)

Country Link
US (8) US8778340B2 (enExample)
EP (3) EP3064509A3 (enExample)
JP (6) JP2013520442A (enExample)
KR (4) KR20180028561A (enExample)
CN (3) CN110227154A (enExample)
AR (1) AR080244A1 (enExample)
AU (5) AU2011221229B2 (enExample)
BR (1) BR112012020700A8 (enExample)
CA (2) CA2787952C (enExample)
CL (1) CL2012002326A1 (enExample)
CO (1) CO6592072A2 (enExample)
IL (2) IL221058B (enExample)
MA (1) MA34059B1 (enExample)
MX (3) MX369170B (enExample)
PH (2) PH12012501681A1 (enExample)
RU (1) RU2012140447A (enExample)
SG (2) SG10201401123VA (enExample)
TW (2) TWI619509B (enExample)
UA (1) UA114277C2 (enExample)
WO (1) WO2011106300A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Vegf/dll4結合剤およびその使用
BR112014018964A2 (pt) * 2012-03-13 2020-05-12 F. Hoffmann-La Roche Ag Anticorpo anti-vegf e uso de um anticorpo anti-vegf
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
MX381141B (es) 2014-02-10 2025-03-12 Merck Patent Gmbh INHIBICIÓN DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
UA120611C2 (uk) * 2014-04-04 2020-01-10 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний засіб, який містить таксанову сполуку і підсилювач протипухлинного ефекту
SG11201609168PA (en) * 2014-05-07 2016-12-29 Medimmune Llc Methods of using anti-ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
MX2017006201A (es) * 2014-11-14 2017-07-31 Genentech Inc Respuesta de prediccion a un antagonista de vegf.
KR102700777B1 (ko) * 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3272771A1 (en) * 2016-07-22 2018-01-24 Centre National De La Recherche Scientifique Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112023018305A2 (pt) * 2021-03-10 2023-10-31 Canariabio Inc Uso de oregovomabe e bevacizumabe, paclitaxel, carboplatina para tratamento de recidiva de brca do tipo selvagem sensível à platina
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
EP4504260A1 (en) * 2022-04-04 2025-02-12 Merck Sharp & Dohme LLC Methods for treating cancer, an infectious disease or an infection using a combination of a tigit antagonist, a pd-1 antagonist, and a vegf antagonist

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US991302A (en) * 1910-03-28 1911-05-02 Frederick G Hepburn Waste-supporter.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0666868B2 (en) 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CN101665536B (zh) 1997-04-07 2013-07-03 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-vegf 항체
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20160014775A (ko) * 2003-05-30 2016-02-11 제넨테크, 인크. 항-vegf 항체를 사용한 치료
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
HUE058817T2 (hu) 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0817182A2 (pt) * 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
AR074203A1 (es) 2008-11-22 2010-12-29 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.

Similar Documents

Publication Publication Date Title
JP2013173775A5 (enExample)
JP2013520442A5 (enExample)
JP2017514795A5 (enExample)
HRP20200921T1 (hr) Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3
JP2015532292A5 (enExample)
JP2012509889A5 (enExample)
JP2017501157A5 (enExample)
JP2011046732A5 (enExample)
JP2013510868A5 (enExample)
JP2019536806A5 (enExample)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2020500538A5 (enExample)
JP2019506403A5 (enExample)
JP2018536624A5 (enExample)
HRP20230517T1 (hr) Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka
RU2012140447A (ru) Антиангиогенная терапия для лечения рака яичника
HRP20170059T1 (hr) Uporaba protutijela anti-vegf u kombinaciji s kemoterapijom za liječenje raka dojke
JP2017501167A5 (enExample)
JP2018507220A5 (enExample)
JP2017528476A5 (enExample)
JP2018508512A5 (enExample)
JP2017031160A5 (enExample)
JP2015519052A5 (enExample)
JP2015522252A5 (enExample)
JP2015530399A5 (enExample)